The effect of adjuvant imatinib treatment for patients with high-risk gastrointestinal stromal tumor
BackgroundImatinib mesylate (IM) has changed the management of gastrointestinal stromal tumors (GISTs), especially for adjuvant therapy after radical resection. However, the optimal duration of the adjuvant therapy remains controversial. Therefore, this study evaluated the effect of adjuvant IM dura...
Enregistré dans:
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2026-04-01
|
| Collection: | Frontiers in Oncology |
| Sujets: | |
| Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fonc.2026.1756927/full |
| Tags: |
Pas de tags, Soyez le premier à ajouter un tag!
|